Cited 0 time in
Medically treated renin-mediated hypertension suspected to be caused by reninoma
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Choi, Hye Min | - |
| dc.contributor.author | Park, Hyeon Keun | - |
| dc.contributor.author | Yang, Ki Hyuk | - |
| dc.contributor.author | Joo, Young Su | - |
| dc.contributor.author | Kwon, Young Eun | - |
| dc.contributor.author | Oh, Dong-Jin | - |
| dc.date.accessioned | 2026-04-27T00:00:08Z | - |
| dc.date.available | 2026-04-27T00:00:08Z | - |
| dc.date.issued | 2025-08 | - |
| dc.identifier.issn | 1470-3203 | - |
| dc.identifier.issn | 1752-8976 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/212335 | - |
| dc.description.abstract | Background: Reninoma, a renin-secreting tumor, is a rare but curable cause of secondary hypertension, typically treated with surgical resection. However, data on pharmacological management of cases where surgery is not feasible remain limited. Case presentation: A 35-year-old man presented with pontine hemorrhage, severe hypertension (252/165 mmHg), hypokalemia, and metabolic alkalosis. Laboratory evaluation revealed a serum creatinine level of 4.6 mg/dL and markedly elevated plasma renin and aldosterone levels. Renin-mediated hypertension due to suspected reninoma was considered after ruling out renal artery stenosis, and lateralized renin secretion was confirmed using renal vein renin sampling. Surgical resection was deferred because of decreased renal function and the uncertain location of the suspected tumor. The patient was treated with an angiotensin II receptor blocker and a low-dose aldosterone antagonist. Blood pressure improved within 1 day, and hypokalemia resolved without potassium supplementation. At the most recent outpatient follow-up, his office blood pressure was 134/78 mmHg while his serum creatinine level remained stable at 2.5 mg/dL. Conclusion: For patients with suspected reninoma who are not candidates for surgery, medical therapy targeting the renin-angiotensin-aldosterone system may offer a safe and effective alternative for achieving long-term stability in blood pressure and renal function. | - |
| dc.format.extent | 7 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | SAGE PUBLICATIONS INC | - |
| dc.title | Medically treated renin-mediated hypertension suspected to be caused by reninoma | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1177/14703203251369237 | - |
| dc.identifier.scopusid | 2-s2.0-105025701962 | - |
| dc.identifier.wosid | 001551744700001 | - |
| dc.identifier.bibliographicCitation | JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, v.26, pp 1 - 7 | - |
| dc.citation.title | JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM | - |
| dc.citation.volume | 26 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 7 | - |
| dc.type.docType | Editorial Material | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
| dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
| dc.subject.keywordPlus | JUXTAGLOMERULAR CELL TUMOR | - |
| dc.subject.keywordPlus | DIAGNOSIS | - |
| dc.subject.keywordAuthor | renin | - |
| dc.subject.keywordAuthor | hypokalemia | - |
| dc.subject.keywordAuthor | metabolic alkalosis | - |
| dc.subject.keywordAuthor | hypertension | - |
| dc.subject.keywordAuthor | reninoma | - |
| dc.subject.keywordAuthor | angiotensin II receptor blocker | - |
| dc.identifier.url | https://journals.sagepub.com/doi/10.1177/14703203251369237 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
